Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy

• Published in: Pharmaceutics Vol. 16; no. 7; p. 938
• Main Authors: Sun, Huiyan, Wang, Xinxia, Li, Yongqiang, Shen, Yingzhi, Zhang, Lin, Xu, Yingjie, Liu, Junling, Fan, Xuemei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.07.2024
• Subjects: CRISPR; Drug delivery systems; Drugs; FDA approval; GalNAc-siRNA; hyperuricemia; Kidney diseases; Laboratory animals; Liver; Mortality; Potassium; Reagents; Rheumatism; Transgenic animals; Uric acid; xanthine oxidoreductase; United States > US; China; Japan; hyperuricemia; xanthine oxidoreductase; GalNAc-siRNA

Hyperuricemia, i.e., increased plasma uric acid concentration, is a common problem in clinical practice, leading to gout or nephrolithiasis, and is associated with other disorders, such as metabolic syndrome, cardiovascular disease, and chronic renal disease. Xanthine oxidoreductase (XOR) is a criti...